Aktis Oncology Launches with $318M IPO to Advance Radiopharmaceutical Cancer Therapies

Aktis Oncology’s sizeable IPO reflects growing investor interest in innovative radiopharmaceutical approaches for cancer. The company’s pipeline focuses on miniprotein radioconjugates aimed at targeted radiation delivery, and it benefits from a discovery partnership with Eli Lilly.

TCB TeamJan 9, 20265 min

IPO Details and Strategic Focus

Aktis Oncology raised $318 million in its initial public offering, the first biotech IPO of 2026.
The company focuses on developing miniprotein radioconjugates for targeted cancer radiation treatment.
A discovery partnership with Eli Lilly underpins Aktis’ pipeline development efforts.

Significance for Cancer Radiopharmaceuticals

Radioconjugates are a promising modality offering targeted delivery with potential advantages over current radiation approaches.
The IPO proceeds are intended to support advancing multiple candidates through clinical development and expanding pipeline reach.

Source: MedCity News

The Catalyst Brief

Independent biotech intelligence, every week.

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.